The stable solid-state drug dosage forms include (a) 0.25-1.25 mg delay agent; (b) 10:1-1:10 and (c) antioxidant in diluent, from antioxidant to after-treatment compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound co

摘要

A stable Solid pharmaceutical dosage form comprising 0.25 to 1.25 mg atrasentan) and (b) an Antioxidant, wherein the molar ratio of Oxidant to atrasentan is 10: 1 to 1: 10, and (c) a diluent; Container that comprises, useful for the treatment of nephropathy.